Realtidsuppskattning
Andra börsplatser
|
5-dagars förändring | Förändring 1 jan. | ||
775,00 DKK | +2,92 % |
|
+3,36 % | +5,24 % |
29.01. | SEB sänker Zealand Pharma till behåll (köp), riktkurs 800 danska kronor - BN | FW |
24.01. | Novo Nordisk stiger på positiva resultat för amycretin - viktminskning på 22 procent (uppdatering) | FW |
Skatteperiod: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 41,33 mn | 353 mn | 293 mn | 104 mn | 343 mn | |||||
Total Revenues | 41,33 mn | 353 mn | 293 mn | 104 mn | 343 mn | |||||
Cost of Goods Sold, Total | 415 tn | 90,56 mn | 119 mn | - | 688 mn | |||||
Gross Profit | 40,92 mn | 263 mn | 174 mn | 104 mn | −345 mn | |||||
Selling General & Admin Expenses, Total | 67,88 mn | 468 mn | 636 mn | 270 mn | 216 mn | |||||
Stock-Based Compensation (IS) | - | - | - | −11,24 mn | - | |||||
R&D Expenses | 561 mn | 604 mn | 588 mn | 612 mn | - | |||||
Other Operating Expenses | −444 tn | −602 tn | −759 tn | 48,27 mn | - | |||||
Other Operating Expenses, Total | 629 mn | 1,07 md | 1,22 md | 918 mn | 216 mn | |||||
Operating Income | −588 mn | −809 mn | −1,05 md | −814 mn | −561 mn | |||||
Interest Expense, Total | −3,2 mn | −2,9 mn | −4,09 mn | −57,79 mn | −25,83 mn | |||||
Interest And Investment Income | 6,29 mn | 1,09 mn | 44 tn | 6,54 mn | 45,32 mn | |||||
Net Interest Expenses | 3,09 mn | −1,81 mn | −4,05 mn | −51,25 mn | 19,49 mn | |||||
Currency Exchange Gains (Loss) | 5,52 mn | −39,49 mn | 39,32 mn | 25,6 mn | −9,71 mn | |||||
Other Non Operating Income (Expenses) | −185 tn | −4,83 mn | −3,47 mn | 11,01 mn | −1,99 mn | |||||
EBT, Excl. Unusual Items | −580 mn | −855 mn | −1,02 md | −829 mn | −553 mn | |||||
Restructuring Charges | - | - | - | −19,1 mn | - | |||||
Merger & Related Restructuring Charges | - | −7,1 mn | - | - | - | |||||
Gain (Loss) On Sale Of Investments | 2,85 mn | −1,17 mn | −6,36 mn | 2,34 mn | −8,84 mn | |||||
Gain (Loss) On Sale Of Assets | - | - | - | - | - | |||||
Asset Writedown | - | −12,74 mn | −2,17 mn | −3,99 mn | −11 mn | |||||
Other Unusual Items | - | 36,4 mn | - | −123 mn | −136 mn | |||||
EBT, Incl. Unusual Items | −577 mn | −840 mn | −1,03 md | −972 mn | −709 mn | |||||
Income Tax Expense | −5,14 mn | 7,08 mn | −8,79 mn | −6,43 mn | −5,13 mn | |||||
Earnings From Continuing Operations | −572 mn | −847 mn | −1,02 md | −966 mn | −704 mn | |||||
Earnings Of Discontinued Operations | - | - | - | −237 mn | - | |||||
Net Income to Company | −572 mn | −847 mn | −1,02 md | −1,2 md | −704 mn | |||||
Net Income - (IS) | −572 mn | −847 mn | −1,02 md | −1,2 md | −704 mn | |||||
Net Income to Common Incl Extra Items | −572 mn | −847 mn | −1,02 md | −1,2 md | −704 mn | |||||
Net Income to Common Excl. Extra Items | −572 mn | −847 mn | −1,02 md | −966 mn | −704 mn | |||||
Per aktie poster | ||||||||||
Net EPS - Basic | −16,91 | −22,07 | −23,75 | −26,02 | −12,44 | |||||
Basic EPS - Continuing Operations | −16,91 | −22,07 | −23,75 | −20,9 | −12,44 | |||||
Basic Weighted Average Shares Outstanding | 33,8 mn | 38,37 mn | 42,87 mn | 46,2 mn | 56,59 mn | |||||
Net EPS - Diluted | −16,91 | −22,07 | −23,75 | −26,02 | −12,44 | |||||
Diluted EPS - Continuing Operations | −16,91 | −22,07 | −23,75 | −20,9 | −12,44 | |||||
Diluted Weighted Average Shares Outstanding | 33,8 mn | 38,37 mn | 42,87 mn | 46,2 mn | 56,59 mn | |||||
Normalized Basic EPS | −10,72 | −13,93 | −14,85 | −11,21 | −6,11 | |||||
Normalized Diluted EPS | −10,72 | −13,93 | −14,85 | −11,21 | −6,11 | |||||
American Depositary Receipts Ratio (ADR) | 1 | 1 | 1 | 1 | 1 | |||||
Kompletterande punkter | ||||||||||
EBITDA | −583 mn | −792 mn | −1,02 md | −727 mn | −555 mn | |||||
EBITA | −588 mn | −802 mn | −1,04 md | −814 mn | −561 mn | |||||
EBIT | −588 mn | −809 mn | −1,05 md | −814 mn | −561 mn | |||||
EBITDAR | - | - | - | - | - | |||||
Effective Tax Rate - (Ratio) | 0,89 | −0,84 | 0,86 | 0,66 | 0,72 | |||||
Normalized Net Income | −362 mn | −534 mn | −637 mn | −518 mn | −346 mn | |||||
Interest on Long-Term Debt | 3,39 mn | 7,72 mn | 7,56 mn | 57,79 mn | 28,98 mn | |||||
Kompletterande driftskostnadsposter | ||||||||||
Selling and Marketing Expenses | - | 273 mn | 375 mn | 32,3 mn | 30,63 mn | |||||
General and Administrative Expenses | 67,88 mn | 196 mn | 261 mn | 237 mn | 185 mn | |||||
Research And Development Expense From Footnotes | 561 mn | 604 mn | 588 mn | 614 mn | 685 mn | |||||
Net Rental Expense, Total | - | - | - | - | - | |||||
Imputed Operating Lease Interest Expense | - | - | - | - | - | |||||
Imputed Operating Lease Depreciation | - | - | - | - | - | |||||
Stock-Based Comp., COGS (Total) | - | - | 521 tn | - | 29,76 mn | |||||
Stock-Based Comp., R&D Exp. (Total) | 12,19 mn | 14 mn | 22,16 mn | 33,84 mn | - | |||||
Stock-Based Comp., S&M Exp. (Total) | - | 6,04 mn | 2,26 mn | 649 tn | 1,73 mn | |||||
Stock-Based Comp., G&A Exp. (Total) | 2,57 mn | 10,44 mn | 27,97 mn | 31,7 mn | 29,94 mn | |||||
Stock-Based Comp., Other (Total) | - | - | - | −11,24 mn | - | |||||
Total Stock-Based Compensation | 14,76 mn | 30,48 mn | 52,91 mn | 54,94 mn | 61,43 mn |